Peter Gerhardsson1, Anke Schwandt2,3, Michael Witsch4, Olga Kordonouri5, Jannet Svensson6,7, Gun Forsander8, Tadej Battelino9, Henk Veeze10, Thomas Danne5,11. 1. Department of Epidemiology, Institute of Applied Economics and Health Research, Copenhagen, Denmark. 2. Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany. 3. German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany. 4. Department of Pediatrics DCCP, Center Hospitalier de Luxembourg, Luxembourg, Luxembourg. 5. Children's Hospital AUF DER BULT, Hannover Medical School, Hannover, Germany. 6. Department of Pediatrics and Adolescents, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark. 7. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 8. Department of Pediatrics, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and Region Västra Götaland, Sahlgrenska University Hospital, Queen Silvia Children's Hospital, Gothenburg, Sweden. 9. UMC-University Children's Hospital and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 10. Diabeter, Diabetes Center for Pediatric and Adolescent Diabetes Care and Research, Rotterdam, Netherlands. 11. SWEET e.V., Hannoversche Kinderheilanstalt, Hannover, Germany.
Abstract
Objective: The international SWEET registry (NCT04427189) was initiated in 2008 to improve outcomes in pediatric diabetes. A 10-year follow-up allowed studying time trends of key quality indicators in 22 centers from Europe, Australia, Canada, and India in youth with type 1 diabetes (T1D). Methods: Aggregated data per person with T1D <25 years of age were compared between 2008-2010 and 2016-2018. Hierarchic linear and logistic regression models were applied. Models were adjusted for gender, age-, and diabetes duration groups. Results: The first and second time periods included 4930 versus 13,654 persons, 51% versus 52% male, median age 11.3 [Q1; Q3: 7.9; 14.5] versus 13.3 [9.7; 16.4] years, and T1D duration 2.9 [0.8; 6.4] versus 4.2 [1.4; 7.7] years. The adjusted hemoglobin A1C (HbA1c) improved from 68 (95% confidence interval [CI]: 66-70) to 63 (60; 65) mmol/mol (P < 0.0001) or 8.4 (95% CI: 8.2-8.6) to 7.9 (7.6; 8.1) % (P < 0.0001). Across all age groups, HbA1c was significantly lower in pump and sensor users. Severe hypoglycemia declined from 3.8% (2.9; 5.0) to 2.4% (1.9; 3.1) (P < 0.0001), whereas diabetic ketoacidosis events increased significantly with injection therapy only. Body mass index-standard deviation score also showed significant improvements 0.55 (0.46; 0.64) versus 0.42 (0.33; 0.51) (P < 0.0001). Over time, the increase in pump use from 34% to 44% preceded the increase in HbA1c target achievement (<53 mmol/mol) from 21% to 34%. Conclusions: Twice yearly benchmarking within the SWEET registry was associated with significantly improved HbA1c on a background of increasing pump and sensor use for 10 years in young persons with T1D. Trial Registration: NCT04427189.
Objective: The international SWEET registry (NCT04427189) was initiated in 2008 to improve outcomes in pediatric diabetes. A 10-year follow-up allowed studying time trends of key quality indicators in 22 centers from Europe, Australia, Canada, and India in youth with type 1 diabetes (T1D). Methods: Aggregated data per person with T1D <25 years of age were compared between 2008-2010 and 2016-2018. Hierarchic linear and logistic regression models were applied. Models were adjusted for gender, age-, and diabetes duration groups. Results: The first and second time periods included 4930 versus 13,654 persons, 51% versus 52% male, median age 11.3 [Q1; Q3: 7.9; 14.5] versus 13.3 [9.7; 16.4] years, and T1D duration 2.9 [0.8; 6.4] versus 4.2 [1.4; 7.7] years. The adjusted hemoglobin A1C (HbA1c) improved from 68 (95% confidence interval [CI]: 66-70) to 63 (60; 65) mmol/mol (P < 0.0001) or 8.4 (95% CI: 8.2-8.6) to 7.9 (7.6; 8.1) % (P < 0.0001). Across all age groups, HbA1c was significantly lower in pump and sensor users. Severe hypoglycemia declined from 3.8% (2.9; 5.0) to 2.4% (1.9; 3.1) (P < 0.0001), whereas diabetic ketoacidosis events increased significantly with injection therapy only. Body mass index-standard deviation score also showed significant improvements 0.55 (0.46; 0.64) versus 0.42 (0.33; 0.51) (P < 0.0001). Over time, the increase in pump use from 34% to 44% preceded the increase in HbA1c target achievement (<53 mmol/mol) from 21% to 34%. Conclusions: Twice yearly benchmarking within the SWEET registry was associated with significantly improved HbA1c on a background of increasing pump and sensor use for 10 years in young persons with T1D. Trial Registration: NCT04427189.
Authors: Faisal S Malik; Katherine A Sauder; Scott Isom; Beth A Reboussin; Dana Dabelea; Jean M Lawrence; Alissa Roberts; Elizabeth J Mayer-Davis; Santica Marcovina; Lawrence Dolan; Daria Igudesman; Catherine Pihoker; Jean M Lawrence; Peggy Hung; Corinna Koebnick; Xia Li; Eva Lustigova; Kristi Reynolds; David J Pettitt; Elizabeth J Mayer-Davis; Amy Mottl; Joan Thomas; Malaka Jackson; Lisa Knight; Angela D Liese; Christine Turley; Deborah Bowlby; James Amrhein; Elaine Apperson; Bryce Nelson; Dana Dabelea; Anna Bellatorre; Tessa Crume; Richard F Hamman; Katherine A Sauder; Allison Shapiro; Lisa Testaverde; Georgeanna J Klingensmith; David Maahs; Marian J Rewers; Paul Wadwa; Stephen Daniels; Michael G Kahn; Greta Wilkening; Clifford A Bloch; Jeffrey Powell; Kathy Love-Osborne; Diana C Hu; Lawrence M Dolan; Amy S Shah; Debra A Standiford; Elaine M Urbina; Catherine Pihoker; Irl Hirsch; Grace Kim; Faisal A Malik; Lina Merjaneh; Alissa Roberts; Craig Taplin; Joyce Yi-Frazier; Natalie Beauregard; Cordelia Franklin; Carlo Gangan; Sue Kearns; Mary Klingsheim; Beth Loots; Michael Pascual; Carla Greenbaum; Giuseppina Imperatore; Sharon H Saydah; Barbara Linder; Santica M Marcovina; Alan Chait; Noemie Clouet-Foraison; Jessica Harting; Greg Strylewicz; Ralph D'Agostino; Elizabeth T Jensen; Lynne E Wagenknecht; Ronny A Bell; Ramon Casanova; Jasmin Divers; Maureen T Goldstein; Leora Henkin; Scott Isom; Kristin Lenoir; June Pierce; Beth Reboussin; Joseph Rigdon; Andrew Michael South; Jeanette Stafford; Cynthia Suerken; Brian Wells; Carrie Williams Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112
Authors: Arcelia Arrieta; Tadej Battelino; Andrea E Scaramuzza; Julien Da Silva; Javier Castañeda; Toni L Cordero; John Shin; Ohad Cohen Journal: Diabetes Obes Metab Date: 2022-05-12 Impact factor: 6.408